Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Gregory Masters (NPI 1508834680)

Field	Value
Entity Type	Individual
Organization	Gregory Masters
Address	4701 Ogletown Stanton Rd
City	Newark
State	DE
ZIP	19713
Taxonomy	Medical Oncology Physician
NPI Enumerated	March 14, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

GREGORY MASTERS is a Medical Oncology physician with an NPI enumerated on 2006-03-14 (~20 years ago) and a lifetime Medicare revenue of $2.3M; there is no Medicaid billing on file, so the provider effectively operates with a single-payer footprint concentrated in Medicare. This tenure suggests established practice experience in oncology care, but the lack of Medicaid activity means payer diversification is minimal.

The provider’s Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes by revenue account for 81.2% of this provider's total Medicare revenue, driven by J9271 (56.3%), J9022 (17.2%), and J9299 (7.7%). That concentration indicates the practice derives the bulk of its billing from a narrow set of high-cost oncologic injectables rather than a broad mix of office or procedural revenue.

The code mix (J9271, J9022, J9299) and associated descriptions identify a practice structured around infusion/administration of immune checkpoint inhibitors and targeted oncology infusions—J9271 (pembrolizumab), J9022 (atezolizumab), and J9299 (nivolumab) are all systemic anticancer injections. Ancillary supportive and specialty oncology agents such as J0897 (denosumab, $138.2K) and J9144 (daratumumab, $123.1K) further point to a treatment portfolio that includes bone-targeting agents and myeloma therapy, consistent with a drug-administration–centric oncology clinic.

J9271 shows especially high relative activity: 30.6K claims, $1.3M revenue, and it ranks #114 of 1841 providers nationally (94th percentile; notably above typical national volume for this code), which the supplied labels characterize as notably above typical national volume. This indicates the provider is a major national-volume participant for pembrolizumab administration and that much of the Medicare revenue base is volume-driven on this single immunotherapy.

Other top codes show mixed competitive standing: J9022 (6.3K claims, $400.9K revenue) ranks #9 of 39 providers nationally (79th percentile; typical, unremarkable volume for this code), while J9299 (7.5K claims, $181K revenue) ranks #416 of 505 (18th percentile; typical, unremarkable volume for this code). In plain terms, the practice has a strong presence for some agents (J9271) and a more modest or typical footprint for other checkpoint inhibitors, rather than uniformly dominant positions across all immunotherapies.

Operational activity beyond drug lines is present but secondary: chemotherapy administration and E/M codes appear in the top 25 but represent much smaller shares of revenue (96413 $46.7K, 99214 $39.2K, 96417 $7.1K). Office visits and infusion administration codes (for example 99214 ranks #68167 of 479517 providers nationally, 86th percentile) indicate routine outpatient management and infusion throughput, but these services are not the primary revenue drivers compared with the high-volume J-code administrations.

The provider’s payment profile reflects volume-based revenue rather than unusually high per-claim reimbursement: for example, J9271 shows 30.6K claims at $43 avg paid/claim producing $1.3M revenue, and J9022 shows 6.3K claims at $64 avg paid/claim producing $400.9K revenue. This pattern—large claim counts with modest average paid per claim—supports an infusion-practice model where throughput of high-cost drugs drives total dollars.

From a payer and contracting perspective, the practice’s reliance on Medicare ($2.3M) with no Medicaid billing on file concentrates reimbursement risk on a single public payer and on a small set of agents (top 3 = 81.2% of Medicare revenue). Analysts evaluating network negotiations or capacity planning should treat this provider as a specialized, infusion-focused oncology source whose financial exposure is tied closely to national utilization patterns for a few checkpoint inhibitors and related oncology injectables.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

35 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	30,600	$40	$1.3M
J9022	Injection, atezolizumab, 10 mg	6,260	$60	$400.9K
J9299	Injection, nivolumab, 1 mg	7,540	$20	$181K
J0897	Injection, denosumab, 1 mg	7,680	$20	$138.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	3,240	$40	$123.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$100	$46.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	400	$100	$39.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	90	$340	$29.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	110	$140	$14.7K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	70	$150	$9.8K

Showing 1–10 of 35

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 35 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Gregory Masters — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

35 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	10	17,600	$40	$992.4K
J9144	6	10	9,360	$40	$420.8K
J9022	1	10	6,260	$60	$402.8K
J9299	3	10	14,300	$20	$329.6K
J0897	13	60	3,360	$20	$132.9K
J1454	5	10	90	$340	$38.1K
96413	8	30	280	$100	$36.6K
99214	424	1,830	150	$80	$25.5K
96401	24	30	110	$60	$18.4K
99233	394	500	80	$90	$15.4K

Showing 1–10 of 35

Related Providers

Other providers that share a Tax Identification Number (TIN) with Gregory Masters, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical Oncology Hematology Consultants PA	DE	Hematology & Oncology Physician	$0	$7.7M
Jamal Misleh	DE	Hematology & Oncology Physician	$6.8M	$0
Dhaval Shah	DE	Hematology & Oncology Physician	$2.5M	$0
Evan Lapinsky	DE	Hematology & Oncology Physician	$1.7M	$0
Lydia Clements	DE	Medical Oncology Physician	$1.3M	$0
Sujung Park	DE	Hematology & Oncology Physician	$1.2M	$0
Amy Mcghee Jez	DE	Hematology & Oncology Physician	$1.1M	$0
Andrew Himelstein	DE	Hematology & Oncology Physician	$1.1M	$0
Roberto Ferro Valdes	SD	Hematology & Oncology Physician	$1.1M	$0
Martha Hosford Skapof	DE	Hematology & Oncology Physician	$748.2K	$0

Nearby Providers

Other providers in the same ZIP code as Gregory Masters, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Columbus Medical Services, LLC	DE	Case Management Agency	$0	$18.7M
Christiana Care Health Services Inc	DE	Hospitalist Physician	$0	$13.6M
Caritas Home Health Services, Inc	DE	Home Health Agency	$0	$11.2M
Delaware Center For Maternal Fetal Medicine Of Christiana Care	DE	Maternal & Fetal Medicine Physician	$0	$9.8M
Christiana Care Health Services Inc	DE	Neonatal-Perinatal Medicine Physician	$0	$8.9M
Christiana Care Quality Partners	DE	Urgent Care Clinic/Center	$0	$7M
Mid-atlantic Behavioral Health, LLC	DE	Intellectual & Developmental Disabilities Psychologist	$0	$6.5M
First State Orthopaedics, PA	DE	Orthopaedic Surgery Physician	$0	$6M
Autism Delaware	DE	Intellectual & Developmental Disabilities Psychologist	$0	$5.8M

Gregory Masters — Billing Profile & Reimbursement Data

Sign up for Gregory Masters — Billing Profile & Reimbursement Data policy alerts

Gregory Masters — Billing Profile & Reimbursement Data

Sign up for Gregory Masters — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References